Skip to main content
TipRanks
Go Ultimate75% OFF

Inhibikase Therapeutics (IKT) Stock Price & Analysis

379 Followers

IKT Stock Chart & Stats

$1.52-$0.01(-0.65%)
At close: 4:00 PM EST
$1.5$2$2.5Aug 17Aug 31Sep 14Sep 28Oct 12Oct 26Nov 9
Day’s Range
$1.49 - $1.58
52-Week Range
$1.40 - $2.61
Previous Close
$1.53
Volume
N/A
Average Volume (3M)
636.65K
Market Cap
$213.21M
Enterprise Value
$211.39M
Total Cash (Recent Filing)
$193.32M
Total Debt (Recent Filing)
$0
Price to Earnings (P/E)
―
Beta
1.85
Next Earnings
Apr 01, 2027 (Est.)
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Low Leverage And Strengthened Equity Base

Effectively zero debt reduces solvency and interest-burden risk while the expanded equity base provides financial support for clinical development. This gives Inhibikase greater flexibility to fund operations and pursue its lead program without the constraints associated with heavy leverage.

Late-stage Clinical Progress

A broad, actively enrolling Phase 3 program represents meaningful advancement toward a potential commercial product. Orphan designation and the 505(b)(2) pathway may streamline development and regulatory review, improving the program’s strategic position over the next several quarters.

Strengthened Clinical And Regulatory Expertise

Adding an independent director with experience developing and securing approval for cardiovascular and metabolic drugs can strengthen oversight during a pivotal trial. His background is relevant to clinical execution, regulatory strategy, and preparation for potential commercialization.

Bears Say

Pre-revenue Business Model

With no reported product revenue, Inhibikase remains dependent on financing while it advances clinical candidates. The absence of recurring operating revenue means commercial progress is still contingent on successful development and approval, leaving the business exposed to execution risk.

Rapidly Widening Losses

The accelerating loss trajectory reflects rising spending before commercialization and reduces the company’s ability to support itself through operations. Persistently larger losses can require additional capital, extend the path to profitability, and increase pressure on future financial resources.

Increasing Cash Burn And Funding Risk

Growing operating cash outflows indicate that reported losses are translating into substantial cash consumption as clinical work advances. Unless spending moderates or revenue begins, continued burn may require future equity or other financing, creating dilution and capital-raising risk.

Inhibikase Therapeutics News

IKT FAQ

What was Inhibikase Therapeutics’s price range in the past 12 months?
Inhibikase Therapeutics lowest stock price was $1.40 and its highest was $2.61 in the past 12 months.
What is Inhibikase Therapeutics’s market cap?
Inhibikase Therapeutics’s market cap is $213.21M.
When is Inhibikase Therapeutics’s upcoming earnings report date?
Inhibikase Therapeutics’s next earnings report is estimated for Apr 01, 2027 (not yet confirmed), which is in 136 days.
How were Inhibikase Therapeutics’s earnings last quarter?
Inhibikase Therapeutics released its earnings results on Nov 10, 2026. The company reported -$0.1 earnings per share for the quarter, beating the consensus estimate of -$0.111 by $0.011.
Is Inhibikase Therapeutics overvalued?
According to Wall Street analysts Inhibikase Therapeutics’s price is currently Undervalued.
Does Inhibikase Therapeutics pay dividends?
Inhibikase Therapeutics does not currently pay dividends.
What is Inhibikase Therapeutics’s EPS estimate?
Inhibikase Therapeutics’s EPS estimate is -0.11.
How many shares outstanding does Inhibikase Therapeutics have?
Inhibikase Therapeutics has 140,269,640 shares outstanding.
What happened to Inhibikase Therapeutics’s price movement after its last earnings report?
Inhibikase Therapeutics reported an EPS of -$0.1 in its last earnings report, beating expectations of -$0.111. Following the earnings report the stock price went up 5.161%.
Which hedge fund is a major shareholder of Inhibikase Therapeutics?
Hedge funds hold Inhibikase Therapeutics shares: the largest hedge-fund position in Inhibikase Therapeutics is 70,128,285 shares, and hedge funds decreased their holdings by 850.4K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology